What “imatinib patent” usually refers to
Imatinib is the active ingredient in several medicines, most notably Gleevec (originally developed by Novartis) for conditions such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). When people search “imatinib patent,” they typically mean one of three things: the expiry of the original compound patent, the expiry of additional “second-wave” patents (new formulations, new uses, dosing/regimens, or manufacturing), or the status of specific regional patents for a given country. [1][2]
When do imatinib patents expire?
Patent expiry depends on the country and the specific patent family. In general, the patent life is tied to the earliest priority filing date, but practical “entry timing” for generics also depends on patent challenges and any regulatory exclusivities or supplementary protections that apply in that market. Because you asked only “Imatinib paten” (likely “patent”), the key missing detail is the jurisdiction (for example, US vs EU vs India) and which patent type you mean (original compound vs later improvements). [1][2]
How can generics enter if patents are still active?
Even if some patents remain in force, generics may enter earlier via:
- Patent “carve-outs” (only launching for indications or claims not covered by an injunction).
- Litigation outcomes that invalidate certain claims or find non-infringement.
- Patent waivers/settlements between brand and generic companies.
- Expiry of the specific patent(s) being asserted, even if other related patents still exist.
So, “patent expiry” is not always the same as “first generic on the shelf” in every country. [1][2]
Why there are multiple imatinib patents (not one single expiry date)
After the initial compound patent, companies commonly file additional patents covering things like:
- Particular formulations (for example, tablet vs dispersible or other dosage forms).
- Additional indications or subpopulations.
- New dosing regimens or combinations.
- Manufacturing processes.
- Improvements that can extend market exclusivity even after the core patent expires.
That means you will often see different expiry dates for different patent documents in the same jurisdiction. [1][2]
Which countries should you check first?
If your goal is to know whether generics can launch in a specific market, the most common places people check are:
- US (FDA approval pathway and relevant Orange Book listings).
- European markets (national patent actions and EMA-related protections).
- UK and other EU member states (often different enforcement timelines).
- India (where regulatory and patent enforcement can differ from US/EU).
- Japan and other major pharma markets.
Without the country, any date would be incomplete or potentially wrong. [1][2]
What I need from you to answer with a real expiry timeline
Tell me:
1) Which country/region (US, EU, UK, India, etc.)?
2) Which product name (Gleevec) or which manufacturer?
3) Do you mean the original imatinib (compound) patent or later patents (formulation/indications)?
With that, I can point to the relevant patent family and the most relevant expiry/launch timing sources. [1][2]
---
Sources
[1] https://patents.google.com/?q=imatinib
[2] https://www.accessdata.fda.gov/scripts/cder/ob/